By François Villeneuve, Head of Market Access & Pricing, Bristol Myers Squibb (BMS) Canada
In a time of significant worldwide need, the pharmaceutical industry has been called on to provide its scientific expertise and address some of the key complexities of the crisis. Collectively, our industry has risen to the occasion, working tirelessly to help find pandemic solutions.
The innovative medicines community has continued to support Canada’s healthcare providers so that one day we can return to a more normal way of life. At the same time, we have worked to overcome many challenges to maintain a consistent supply of life-saving medicines and ensure their distribution to the patients who need us today and in the future. We have also maintained an unwavering focus on research and clinical trial activity for all of the patients who depend on the biopharma healthcare industry to drive innovation forward.
As we all work towards defeating this virus, we are setting a new standard for innovation and scientific progress. In fact, the extraordinary approach to a COVID-19 vaccine and treatment research has been a silver lining to this devastating pandemic. Supporting innovation and a rapid response should continue well beyond this crisis. Imagine moving at this pace on major diseases like cancer and heart disease.
As an industry, we have wholeheartedly demonstrated our commitment to working closely with federal and provincial government agencies during a time of great need. Now, more than ever, Canadians are witnessing the significant contributions that pharma is making to help Canadians prevail over serious disease and how vital innovation is now - and in the future - to creating a sustainable and vibrant healthcare system.
